Introduction
============

*Streptococcus pneumoniae* is a Gram-positive bacterium that colonizes the upper respiratory tract and causes life-threatening pulmonary diseases as well as infections of the brain, the middle ear and the sinuses \[[@R1]--[@R6]\]. Twenty-three of the more than ninety *S. pneumoniae* serotypes, which differ in the capsular polysaccharides (CPS) that surround them, are responsible for about 90% of infections worldwide \[[@R7]\]. The licensed polysaccharide vaccine Pneumovax 23 contains serotype 12F but is not efficacious in young children or elderly people, those at highest risk. The carbohydrate conjugate vaccines Prevanar13™ and Synflorix™ \[[@R8]--[@R11]\] are based on CPS-carrier protein constructs and contain thirteen or ten *S. pneumoniae* serotypes, respectively, but not 12F \[[@R12]--[@R13]\]. The *S. pneumoniae* serotypes 12A \[[@R14]\] and 12F \[[@R15]\] combined account for more than 4% of pneumococcal disease \[[@R16]\], whereby 12F ([Fig. 1](#F1){ref-type="fig"}) dominates with 85% \[[@R17]\]. In order to improve current glycoconjugate vaccines additional serotypes such as 12F should be included in next-generation preparations \[[@R18]\].

![Structure of the *S. pneumoniae* serotype 12F capsular polysaccharide repeating unit \[[@R15]\].](Beilstein_J_Org_Chem-13-164-g002){#F1}

Synthetic oligosaccharides are important tools for the identification of vaccine epitopes and have been the key to the creation of monoclonal antibodies that serve as tools for vaccine design \[[@R19]\] and for the detection of pathogenic bacteria such as *Bacillus anthracis* \[[@R20]--[@R21]\]. *S. pneumoniae* 12F CPS consists of hexasaccharide repeating units containing the \[→4)-α-L-Fuc*p*NAc-(1→3)-β-D-Gal*p*NAc-(1→4)-β-D-Man*p*NAcA-(1→\] polysaccharide backbone with a disaccharide branch at C3 of β-D-Man*p*NAcA and C3 of α-L-Fuc*p*NAc \[[@R15]\]. We established a total synthesis of the hexasaccharide repeat unit as a first step toward a detailed immunological analysis of *S. pneumoniae* 12F.

Results and Discussion
======================

**Retrosynthetic analysis.** Initially, a convergent \[3 + 3\] synthesis of the repeating unit hexasaccharide **1** was envisioned. The union of trisaccharides **2** and **3** ([Scheme 1](#C1){ref-type="fig"}, route A) was identified as the key step. The outcome of this late-stage block coupling was deemed risky considering the poor nucleophilicity of the C4 hydroxy group of the β-mannosazide in **3** combined with steric bulk around the acceptor. Trisaccharides **2** and **3** can be derived from differentially protected common building blocks that carry *tert*-butyldimethylsilyl (TBS), benzoate (Bz) or acetate (Ac) ester and 2-naphthylmethyl (NAP) protecting groups that can be removed sequentially to allow for glycosylation of the liberated hydroxy groups. Formation of the β-mannosazide glycoside containing a protected C~5~ amino linker that serves in the final product as an attachment point for glycan array surfaces or carrier proteins was central to the assembly of trisaccharide **3**. To avoid a challenging and often unselective β-mannoside formation step we resorted to glucose--mannose conversion by inversion of the C2 stereocenter following selective installation of a *trans*-glucosidic linkage. Differentially protected thioglucoside **11** \[[@R22]\] is equipped with a participating C2 levulinyl ester that is replaced by an axial azido group following β-glucoside formation \[[@R23]\].

![Retrosynthetic analyses of the *S. pneumoniae* hexasaccharide **1**.](Beilstein_J_Org_Chem-13-164-g003){#C1}

Alternatively, a linear synthetic strategy in which the sterically hindered C4 hydroxy group would be glycosylated first, followed by the C3 hydroxy group of β-mannosazide building block **4**, was designed in case the convergent approach proved unsuccessful ([Scheme 1](#C1){ref-type="fig"}, route B).

**Building block synthesis.** The accessibility of differentially protected monosaccharide building blocks is a prerequisite for the successful total synthesis of any complex glycan. The synthesis of the mannosazide building block was the first challenge to be addressed. Installation of a C2-participating levulinyl ester protecting group ensured selective formation of the *trans*-glycoside upon activation of **11** by NIS/TfOH in the presence of the C~5~ linker to produce glucoside **12** in 70% yield \[[@R24]\]. Cleavage of the C2 levulinyl ester of **12** by treatment with hydrazine acetate furnished **13**, which was to be carried forward into the C2 inversion step. Conversion of **13** to the corresponding C2 triflate upon treatment with triflic anhydride in pyridine was not successful. Even model thioglycoside **10** failed to react to the corresponding glycosyl triflate under similar conditions ([Scheme 2](#C2){ref-type="fig"}).

![Attempted synthesis of mannosazide building block **15**. Reagents and conditions: (a) levulinic acid, DCC, DMAP, CH~2~Cl~2~, 82%; (b) NIS, TfOH, HO(CH~2~)~5~NBnCbz, CH~2~Cl~2~, −20 °C, 70%; (c) N~2~H~4~, AcOH, pyridine, CH~2~Cl~2~, 70%; (d) Tf~2~O, pyridine, CH~2~Cl~2~, 0 °C to rt.](Beilstein_J_Org_Chem-13-164-g004){#C2}

The problems associated with the lengthy and low yielding synthetic sequence prompted us to explore a different approach to obtain the key mannosazide building block ([Scheme 3](#C3){ref-type="fig"}). Partially protected mannosazide thioglycoside **16** was prepared in seven steps from α-*O*-methylglucose following a published procedure \[[@R25]\]. Silylation of the C3 hydroxy group furnished thioglycoside **17**. Glycosylation of the C~5~ linker by activation of **17** using NIS/TfOH as the promoter at −20 °C produced mainly β-mannoside **15** (4:1 β:α) \[[@R26]\]. The identity of the β-isomer was confirmed by NMR analysis (^1^ *J* ~CH~ β = 159.0 Hz, see [Supporting Information File 1](#SD1){ref-type="supplementary-material"}). Cleavage of the silyl ether by TBAF treatment of **15** afforded the β-mannosazide building block **18**.

![Synthesis of mannosazide building block **18**. Reagents and conditions: (a) TBSCl, imidazole, DCM, 0 °C to rt, 85%; (b) NIS, TfOH, HO(CH~2~)~5~NBnCbz, CH~2~Cl~2~, −20 °C, 61%; (c) TBAF, THF, 0 °C, 80%.](Beilstein_J_Org_Chem-13-164-g005){#C3}

**Convergent \[3 + 3\] synthesis.** Synthesis of the reducing-end trisaccharide **3** ([Scheme 1](#C1){ref-type="fig"}) commenced with the assembly of the α-1→2 linked diglucoside **19** by union of the monosaccharide building blocks **10** and **7** \[[@R27]\] in a dichloromethane--ether (enables alpha selectivity) mixture in 56% yield ([Scheme 4](#C4){ref-type="fig"}). Removal of the silyl ether and benzylidene groups of **19** yielded triol **20** before benzylation afforded disaccharide thioglycoside building block **21**. Activation of disaccharide **21** resulted in the glycosylation of mannosazide acceptor **18** ([Scheme 3](#C3){ref-type="fig"}) to form the corresponding α-linked trisaccharide, which, subsequent to removal of the 4,6-benzylidene group under acidic conditions, provided diol **22** that was in turn converted into reducing-end trisaccharide **3** by selective placement of a TBS ether \[[@R28]\] on the primary alcohol ([Scheme 4](#C4){ref-type="fig"}).

![Synthesis of the reducing-end trisaccharide **3**. Reagents and conditions: (a) TMSOTf, (CH~3~CH~2~)~2~O/CH~2~Cl~2~ (4:1), −20 °C, α/β = 4:1, 70%; (b) *p*-TsOH, CH~3~OH/CH~2~Cl~2~ (1:1), rt, 70%; (c) NaH, benzyl bromide, THF/DMF (1:1), 0 °C to rt, 90%; (d) **18**, NIS, TfOH, (CH~3~CH~2~)~2~O/CH~2~Cl~2~, (4:1), −20 °C, 61%; (e) *p*-TsOH, CH~3~OH, rt, 90%; (f) TBSCl, imidazole, CH~2~Cl~2~, rt, 93%.](Beilstein_J_Org_Chem-13-164-g006){#C4}

With reducing-end trisaccharide **3** in hand, we turned our attention to the synthesis of trisaccharide **2**, which required the availability of three differentially protected monosaccharide building blocks: **8**, **9** and **26** ([Scheme 5](#C5){ref-type="fig"}). Protected building block **26** was obtained in four steps from known galactosylazide selenide **23** \[[@R29]\]. Acetylation of the C3 hydroxy group of **23** furnished fully differentially protected selenoglycoside **24** in 82% yield. Hydrolysis of the selenoglycoside using NIS in aqueous THF produced hemiacetal **25** that was silylated prior to selective saponification of the C3 *O*-acetate to yield building block **26** ([Scheme 5](#C5){ref-type="fig"}).

![Synthesis of monosaccharide building blocks **8**, **9** and **26**. Reagents and conditions: (a) acetic anhydride, pyridine, CH~2~Cl~2~, rt, 18 h, 82%; (b) NIS, THF/H~2~O (1:1), rt; (c) 1) TBDPSCl, imidazole, DMF, rt; 2) NaOMe, MOH, rt, 68% over two steps; (d) (PhSe)~2~, BAIB, NaN~3~, CH~2~Cl~2~, rt, 24 h; (e) NIS, THF/H~2~O (1:1), rt, 80% over two steps; (f) CCl~3~CN, DBU, CH~2~Cl~2~, 0 °C to rt, 2 h, 72%; (g) TES, TFA, CH~2~Cl~2~, 0 °C, 6 h; (h) benzoyl chloride, pyridine, rt, 18 h, 80% over two steps.](Beilstein_J_Org_Chem-13-164-g007){#C5}

Fucosazide building block **8** was derived from diacetyl fucal **27** that in turn was prepared in two steps from L-fucose \[[@R30]\]. Azido-selenation of **27** and hydrolysis of the seleno fucosazide with NIS in aqueos THF \[[@R31]\] provided hemiacetal **28**, which was subsequently converted to the fucosyl trichloroacetimidate building block **8** ([Scheme 5](#C5){ref-type="fig"}). Galactosyl thioglycoside **9** was prepared from D-galactose following published procedures \[[@R32]\]. Reductive opening of the benzylidene acetal of known galactosyl thioglycoside **29** \[[@R33]\] with triethylsilane \[[@R34]\] in TFA/CH~2~Cl~2~ liberated the C4 hydroxy group of **30**, which was subsequently benzoylated to ensure remote participation in **9** for the preferential formation of *cis*-glycosides ([Scheme 5](#C5){ref-type="fig"}) \[[@R35]\].

With the three building blocks **8**, **9** and **26** in hand, the assembly of the non-reducing end trisaccharide **2** commenced. The union of **8** and **26** produced the α-linked disaccharide **31** in 74% yield and excellent α-selectivity due to remote participation of the C2 and C3 acetate esters present in the fucosazide donor ([Scheme 6](#C6){ref-type="fig"}). Preparation of the site for the downstream glycosylation, the C3 hydroxy group in the fucosazide moiety, to obtain **35**, required several protecting group manipulation steps: cleavage of the two acetate esters of **31** to produce diol **32** was followed by the reaction with trimethyl orthoacetate to provide the ortho-ester **33**, which was regioselectively opened under acidic conditions to afford disaccharide acceptor **34** containing a C3 hydroxy group \[[@R28]\]. Glycosylation of disaccharide **34** using galactose building block **9**, activated by NIS/triflic acid, produced trisaccharide **35** with high α-selectivity by virtue of the C4-participating benzoyl ester protecting group of **9** \[[@R36]\]. Trisaccharide **35** was transformed into a glycosylating agent by removal of the anomeric TBDPS silyl ether using HF-pyridine and subsequent treatment with trichloroacetonitrile in the presence of catalytic amounts of DBU to afford glycosyl trichloroacetimidate trisaccharide **2** ([Scheme 1](#C1){ref-type="fig"}).

![Synthesis of the non-reducing end trisaccharide **2**. Reagents and conditions: (a) TMSOTf, CH~2~Cl~2~, −30 °C, 74%; (b) NaOMe (0.5 M in MeOH), MeOH, rt; (c) trimethyl orthoacetate, *p*-TsOH, toluene; (d) 80% AcOH, rt, 71% over three steps; (e) **9**, NIS, TMSOTf, dioxane/toluene (3:1), −10 °C, 54%; (f) HF-pyridine, THF, 0 °C; (g) CCl~3~CN, DBU, CH~2~Cl~2~, 0 °C, 57% over two steps.](Beilstein_J_Org_Chem-13-164-g008){#C6}

With trisaccharide fragments **2** and **3** in hand, the convergent \[3 + 3\] approach ([Scheme 1](#C1){ref-type="fig"}, route A) to the synthesis of the repeating unit hexasaccharide **36** ([Scheme 7](#C7){ref-type="fig"}) was attempted. The union of trisaccharides **2** and **3** using TMSOTf in acetonitrile as the activator did not yield the desired hexasaccharide **36**. Instead, trisaccharide acceptor **3** missing its C6 silyl ether protecting group **38** was recovered. The undesired outcome of this coupling step likely resulted from the poor nucleophilicity of **3** rather than a lack of reactivity of trisaccharide glycosylating agent **2**, as demonstrated by an experiment in which model monosaccharide **37** \[[@R29]\] also failed to react with trisaccharide acceptor **3** and recovered **38** ([Scheme 7](#C7){ref-type="fig"}).

In order to better understand the formation of the key disaccharide GalNAc→ManNAcA, a model glycosylation involving mannosazide **4** ([Scheme 7](#C7){ref-type="fig"}, prepared in four steps from **16**, see [Supporting Information File 1](#SD1){ref-type="supplementary-material"}) was explored. Differentially protected mannosazide **4** was successfully glycosylated using building blocks **5** or **37** to yield the corresponding disaccharide in 21% and 37% yield, respectively. The failure of the \[3 + 3\] coupling to produce hexasaccharide **36** was apparently a result of the poor nucleophilicity of the C4 hydroxy group in **3** rather than of problems associated with the glycosylating agents. The presence of a disaccharide appendage at the C3 position as well as a bulky TBS silyl ether at C6 may block the C4 hydroxy group.

![Attempted synthesis of hexasaccharide repeating unit **36** via a convergent \[3 + 3\] glycosylation strategy and exploratory control experiments. A) Failed \[3 + 3\] glycosylation; B) failed model \[1 + 3\] glycosylation; C) low yielding model coupling of two monosaccharides.](Beilstein_J_Org_Chem-13-164-g009){#C7}

The β-selectivity of glycosylations using glycosylating agents **5** and **37** even in acetonitrile was rather poor. Apparently, the "nitrile effect" \[[@R37]--[@R38]\] is partially overruled by the participating nature of the C3 ester protecting groups Ac/Bz that leads to a preference for the *cis*-glycosidic α-linked product.

**Linear total synthesis of 12F repeating unit hexasaccharide 1.** The failure of the convergent \[3 + 3\] total synthesis approach prompted us to retreat to the linear avenue ([Scheme 1](#C1){ref-type="fig"}, route B) towards the target oligosaccharide in order to avoid the sterically demanding late-stage glycosylation. Differentially protected mannosazide **4** served as the starting point for stepwise assembly from the reducing to the non-reducing end ([Scheme 8](#C8){ref-type="fig"}). Union of **4** and **5** ([Scheme 7](#C7){ref-type="fig"}) produced disaccharide **41** as the key intermediate, the naphthyl protecting group of which was cleaved in 70% yield using DDQ \[[@R37]\] to afford **42**. Thioglycoside **43** failed to react with disaccharide **42** to furnish the desired trisaccharide **44**. Considering a potential "mismatch" \[[@R38]\] between the thioglycoside glycosylating agent and the acceptor \[[@R39]--[@R40]\] we explored whether the glucosyl trichloroacetimidate donor **6** ([Scheme 1](#C1){ref-type="fig"}) would be more suitable. Indeed, glycosylation of disaccharide **42** with building block **6** using TMSOTf as the activator proceeded to produce trisaccharide **44** in 65% yield.

Removal of the C2 naphthyl ether using DDQ provided acceptor **45**, which in turn was reacted with glucosyl thioglycoside **7** in the presence of NIS and TfOH to produce α-linked tetrasaccharide **46** in 62% yield ([Scheme 8](#C8){ref-type="fig"}). At this stage, the 2-azidomannose moiety of **46** was converted to the corresponding mannosaminuronic acid by cleaving the C6 benzoate ester using sodium methoxide in methanol and selective oxidation of the primary alcohol of **47** using BAIB/TEMPO. Tetrasaccharide acceptor **48** was obtained by esterification of the carboxylic acid under basic conditions using methyl iodide in 32% yield over three steps \[[@R41]\]. Next, TMSOTf activation of fucosyl trichloroacetimidate **8** ([Scheme 1](#C1){ref-type="fig"}) catalyzed the glycosylation of methyl uronate **48** to afford pentasaccharide **49** exclusively as the α-isomer by virtue of remote participation of the 3-*O*-acetate group. In anticipation of the final glycosylation, the fucosazide moiety of **49** was converted into acceptor **50**. The desired hexasaccharide **51** was obtained as the α-anomer in 54% yield by coupling galactose building block **9** ([Scheme 1](#C1){ref-type="fig"}) to pentasaccharide **50** using NIS/TfOH in a mixture of toluene/dioxane. Again, the C4 benzoate ester of **9** ensured high selectivity for the desired *cis*-glycosidic linkage.

![Linear assembly of fully protected hexasaccharide **51**. Reagents and conditions: (a) DDQ, CH~2~Cl~2~/MeOH (9:1), rt, 70%; (b) **43**, NIS, TfOH, CH~2~Cl~2~, −20 °C (no reaction) or **6**, TMSOTf, Et~2~O/CH~2~Cl~2~ (4:1), −20 °C (65%); (c) DDQ, CH~2~Cl~2~/MeOH (9:1), rt, 55%; (d) **7**, TMSOTf, Et~2~O/CH~2~Cl~2~ (4:1), −20 °C, 62%; (e) NaOMe (0.5 M in MeOH), THF/MeOH (1:1), rt, 90%; (f) i. TEMPO, BAIB, CH~2~Cl~2~/H~2~O (4:1), rt; ii. MeI, K~2~CO~3~, DMF, rt, 35% over two steps; (g) **8**, TMSOTf, CH~2~Cl~2~, −20 °C, 77%; (h) i. NaOMe (0.5 M in MeOH), THF/MeOH (1:1); ii. trimethyl orthoacetate, *p*-TsOH, toluene; iii. 80% AcOH, rt, 27% over three steps; (i) **9**, NIS, TMSOTf, dioxane/toluene (3:1), −10 °C to 0 °C, 54%.](Beilstein_J_Org_Chem-13-164-g010){#C8}

Global deprotection commenced with the conversion of the three azide groups present in compound **51** into NHAc groups in a single step using thioacetic acid in pyridine \[[@R42]\] afforded triacetamide **52** in 65% yield; it is important to note that Zn-mediated reduction of **51** led to decomposition of the substrate. Ester saponification of **52** employing sodium methoxide in methanol yielded none of the desired product **53** but rather the tentatively assigned β-elimination products **54** and **55**. Furthermore, an attempt at employing a more nucleophilic and less basic reagent such as a lithium hydroxide/hydrogen peroxide mixture did not provide relief from the problem, but instead also produced a mixture of undesired products. Adjustments in the sequence of deprotection steps by first carrying out hydrogenolysis using Pd/C in a mixture of AcOH/H~2~O/*t*-BuOH prior to ester hydrolysis using LiOH/H~2~O~2~ enabled the hexasaccharide **1** to be obtained in 37% yield ([Scheme 9](#C9){ref-type="fig"}).

![Global deprotection to furnish *S. pneumonia* serotype 12F repeating unit hexasaccharide **1**. Reagents and conditions: (a) thioacetic acid, pyridine, rt, 65%; (b) Zn, AcOH/Ac~2~O/THF, Cu~2~SO~4~ (aq, decomposed); saponification conditions that lead to β-elimination (c) i. NaOMe (0.5 M in MeOH) in MeOH, ii. NaOH (4 M, 2 M, 1 M, 0.5 M, 0.1 M) solution in THF, iii. H~2~O~2,~ LiOH, THF, H~2~O; successful sequence (d) Pd/C, AcOH, H~2~O, *t*-BuOH (e) H~2~O~2,~ LiOH, THF, H~2~O, 37% over two steps.](Beilstein_J_Org_Chem-13-164-g011){#C9}

Conclusion
==========

The first total synthesis of the *S. pneumoniae* serotype 12F capsular polysaccharide repeating unit hexasaccharide **1** was achieved by means of a linear approach. A convergent \[3 + 3\] total synthesis strategy failed, most likely due to steric crowding around the trisaccharide acceptor. The synthesis of **1** is an illustrative example of the challenges associated with state-of-the-art oligosaccharide assembly including steric, conformational, remote participation groups and solvent effects. It lends further credence to the linear assembly concept in which one monosaccharide unit at a time is incorporated, and which serves as the basis for automated glycan assembly \[[@R43]\]. With the synthetically sourced hexasaccharide repeating unit in hand detailed immunological analysis of *S. pneumoniae* serotype 12F can be undertaken, and future work will address the expanded inclusion of this antigen in next-generation glycoconjugate vaccines.

Abbreviations
=============

Ac: acetate ester; BAIB: bis(acetoxy)iodobenzene; Bz: benzoyl; CPS: capsular polysaccharide; DMF: *N,N*-dimethylformamide; EtOAc: ethyl acetate; GlcA: glucouronic acid; HPLC: high-performance liquid chromatography; Lev: levulinoyl; MALDI--TOF MS: matrix-assisted laser desorption/ionization--time of flight mass spectrometry; NAP: 2-naphthylmethyl; TBS: *tert*-butyldimethylsilyl; THF: tetrahydrofuran; TMSOTf: trimethylsilyl trifluoromethanesulfonate.
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